Showing results (151-160 of 785) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|August 29, 2024
Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort studyPatrick G A Oomen, Ferdinand W N M Wit, Kees Brinkman, et al.
The Lancet. HIV|September 7, 2024
Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre studyMayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
The Lancet. HIV|June 7, 2024
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluationViviane D Lima, Jielin Zhu, Rolando Barrios, et al.
The Lancet. HIV|May 24, 2024
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial
The Lancet. HIV|April 15, 2024
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohortsDathan M Byonanebye, Mark N Polizzotto, Fernando Maltez, et al.
The Lancet. HIV|January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trialElizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV|February 2, 2026
Cigarette smoking in PrEP recipients: a challenge and an opportunityJonathan Shuter, Nancy A Rigotti, Krishna P Reddy, et al.
The Lancet. HIV|January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm studyAditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Lancet. HIV|January 18, 2026
Assessing the effectiveness of a depression-integrated model in adult HIV care in Uganda (the HIV+D trial): a cluster-randomised controlled trialEugene Kinyanda, Leticia Kyohangirwe, Richard S Mpango, et al.
Pageof 79